“ Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter “ “ Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid...
“ Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation ““ Additional data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat) in adults with desmoid...
STAMFORD, Conn., April 18, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
SpringWorks Initiates Rolling Submission of NDA to the FDA for Mirdametinib
SpringWorks Therapeutics Announces EMA Validation for MAA of Nirogacestat
SpringWorks Announces EMA Validation for MAA of Nirogacestat
Reported OGSIVEO„¢ (nirogacestat) net product revenue of $5.4 million in first partial quarter of launch following FDA approval on November 27, 2023 Submitted Marketing Authorization Application...
STAMFORD, Conn., Feb. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
Where Does SpringWorks Stock Fall in the Biotechnology Field
STAMFORD, Conn., Jan. 31, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...